Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Doxorubicin 25Radiotherapy 15Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Gemcitabine 5Biopsy 5palbociclib 4Magnetic Resonance Spectroscopy 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3X-Rays 3Vincristine 3Radiation 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2cixutumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × silmitasertib × Sarcoma × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡